Breast cancer drug comparison study halted before it began
NCT ID NCT06884254
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 23 times
Summary
This study aimed to see if a new drug called EG1206A works as well as the approved drug Perjeta for people with HER2-positive early breast cancer. Both were given with trastuzumab and chemotherapy before and after surgery. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Methodist Health System Clinical Research Institute
Dallas, Texas, 75023, United States
Conditions
Explore the condition pages connected to this study.